Immuneering (IMRX) Resumen de Acciones
Immuneering Corporation, empresa oncológica en fase avanzada, desarrolla medicamentos para amplias poblaciones de pacientes con cáncer en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
+ 1 riesgos adicionales
IMRX Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Immuneering Corporation
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$5.06 |
| Máximo en las últimas 52 semanas | US$10.08 |
| Mínimo de 52 semanas | US$3.25 |
| Beta | 0.37 |
| Cambio en 1 mes | 9.05% |
| Variación en 3 meses | 3.90% |
| Cambio de 1 año | 34.57% |
| Variación en 3 años | -43.53% |
| Variación en 5 años | -83.37% |
| Variación desde la OPV | -71.23% |
Noticias y actualizaciones recientes
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Summary Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Phase 2a results versus standard-of-care regimens. IMRX's pivotal Phase 3 trial in first-line PDAC is recruiting, with first patient dosing expected mid-2026 and cash runway projected into 2029. Atebimetinib demonstrated median overall survival of 17.3 months, outperforming historical controls and comparing favorably to competitors’ data. Despite strong clinical data and differentiated tolerability, IMRX trades at a deep discount to peers, presenting a high-risk, high-reward opportunity. Read the full article on Seeking AlphaCompanies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Recent updates
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Summary Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Phase 2a results versus standard-of-care regimens. IMRX's pivotal Phase 3 trial in first-line PDAC is recruiting, with first patient dosing expected mid-2026 and cash runway projected into 2029. Atebimetinib demonstrated median overall survival of 17.3 months, outperforming historical controls and comparing favorably to competitors’ data. Despite strong clinical data and differentiated tolerability, IMRX trades at a deep discount to peers, presenting a high-risk, high-reward opportunity. Read the full article on Seeking AlphaCompanies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Pancreatic Cancer Breakthrough And Long Patent Tail Will Transform This Oncology Platform
Catalysts About Immuneering Immuneering is a biotechnology company focused on developing atebimetinib, a MEK inhibitor, for cancers driven by the MAP kinase pathway, with an initial focus on first line pancreatic cancer and expansion into lung cancer and other tumor types. What are the underlying business or industry changes driving this perspective?
Pivotal Pancreatic Cancer Trial And Extended Patent Protection Will Shape A Long Runway
Catalysts About Immuneering Immuneering is a clinical stage biotech company focused on developing atebimetinib, a MEK inhibitor, for cancers driven by the MAP kinase pathway, with an initial focus on first line pancreatic cancer and expansion into lung cancer. What are the underlying business or industry changes driving this perspective?Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Immuneering...Here's Why Immuneering (NASDAQ:IMRX) Must Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Immuneering (NASDAQ:IMRX) Will Have To Spend Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
Summary Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024. Immuneering had $85.7 million in cash as of December 31st of 2023; Enough cash to fund its operations into the 2nd half of 2025. Read the full article on Seeking AlphaIs Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Immuneering wins FDA nod to study lead asset in solid tumors
The development-stage biotech Immuneering Corporation (NASDAQ:IMRX) announced Friday that the FDA greenlighted its Investigational New Drug (IND) application to study IMM-1-104, its lead candidate targeted at advanced RAS mutant solid tumors. Accordingly, the company expects to begin a Phase 1/2a clinical trial to assess the oral, once-daily therapy in advanced RAS mutant solid tumors across five clinical sites in the U.S. IMRX expects to follow the Phase 1 segment of the study with a dose expansion Phase 2a portion targeted at RAS mutated pancreatic, melanoma, colorectal, and lung cancers. The first patient is expected to enroll in Q4 2022. “Clearance of the IND for IMM-1-104 brings us one step closer to our goal of developing medicines with the potential to benefit every cancer patient with a RAS mutant solid tumor, not just those harboring specific mutations,” Chief Executive Ben Zeskind said. The announcement of the IND submission for IMM-1-104 sent IMRX shares higher early this month.Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate
The shares of development-stage biotech Immuneering Corporation (NASDAQ:IMRX) added ~9% in the pre-market trading Friday after the company announced the filing of an Investigational New Drug (IND) seeking FDA clearance to conduct a clinical trial for its lead asset IMM-1-104. An oral once-daily small molecule, IMM-1-104, targets advanced solid tumors with RAS mutations, unlike the candidates that target specific cancer mutations such as KRAS-G12C. “The preclinical data package for IMM-1-104 is uniquely compelling, and we are excited to now evaluate this compound in patients who so urgently need new options,” the Chief Executive of IMRX, Brett Hall, noted. With the IND submission, the FDA will review the company’s application to determine if the data support the safety of IMM-1-104. IMRX plans to conduct a Phase 1/2a clinical trial of IMM-1-104 across five internationally recognized clinical sites in the U.S. Amgen (AMGN) and Mirati Therapeutics (MRTX) are among the developers of cancer therapies targeted at KRAS G12C mutations.Immuneering initiated a Buy by Chardan, PT set to $18
Immuneering (NASDAQ:IMRX) initiated with a Buy by Chardan analyst Geulah Livshits and gave $18 as price target. The analyst likes the potential of Immuneering's pipeline and translational bioinformatics platform to address unmet needs in diverse cancers. The company's approach integrates analysis of high-throughput transcriptional, genomics, and proteomics datasets to generate insights into tumor signaling dynamics, and mechanisms of therapy response or resistance, to advance drug candidates with optimal signaling profiles, Livshits tells investors in a research note. Currently, the stock is trading at $6.3, a rise of ~10.7% on Friday. Stock has slumped about 64% over the last one year and company has a market cap of $139M . The stock is given a Wall Street 'Strong Buy' rating with 4.5 score (4 Strong Buy, 1 Buy, 1 Hold) Comparative rating of the stock against the peers:Rentabilidad de los accionistas
| IMRX | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 12.2% | 0.5% | 0.6% |
| 1Y | 34.6% | 35.8% | 20.1% |
Rentabilidad vs. Industria: IMRX igualó a la industria US Biotechs, que obtuvo un rendimiento del 35.8% el año pasado.
Rentabilidad vs. Mercado: IMRX superó al mercado US, que obtuvo un rendimiento del 20.1% el año pasado.
Volatilidad de los precios
| IMRX volatility | |
|---|---|
| IMRX Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: El precio de las acciones de IMRX ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de IMRX(11%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2008 | 57 | Ben Zeskind | immuneering.com |
Immuneering Corporation, empresa oncológica en fase avanzada, desarrolla medicamentos para amplias poblaciones de pacientes con cáncer en Estados Unidos. La empresa desarrolla IMM-1-104 (atebimetinib), un inhibidor dual de MEK que se encuentra en un ensayo clínico de fase 3 para tratar a pacientes con cáncer, incluido el cáncer de páncreas y el cáncer de pulmón de células no pequeñas causado por mutaciones de RAS o RAF; IMM-6-415 (envometinib), que se encuentra en un ensayo clínico de fase 1/2a para el tratamiento de pacientes con tumores sólidos; y múltiples programas de descubrimiento de inhibidores cíclicos profundos. La empresa tiene acuerdos de suministro clínico con Regeneron Pharmaceuticals para evaluar el atebimetinib en combinación con Libtayo en pacientes con cáncer de pulmón no microcítico con mutación RAS irresecable o metastásico; y con Eli Lilly and Company para evaluar el atebimetinib en combinación con olomorasib en pacientes con cáncer de pulmón no microcítico con mutación KRAS G12C avanzado o metastásico.
Resumen de fundamentos de Immuneering Corporation
| Estadísticas fundamentales de IMRX | |
|---|---|
| Capitalización bursátil | US$327.37m |
| Beneficios(TTM) | -US$57.28m |
| Ingresos (TTM) | n/a |
¿Está IMRX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de IMRX | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$57.28m |
| Beneficios | -US$57.28m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.89 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado IMRX a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/16 05:04 |
| Precio de las acciones al final del día | 2026/08/14 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Immuneering Corporation está cubierta por 11 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Andres Maldonado | H.C. Wainwright & Co. |